KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.

Emmanuel Chigutsa, Lucy Her, Xiaosu Ma, Shweta Urva, Karen Schneck

Clin Pharmacol Ther 118(6) 1489-1498

PMID40556483
PMCIDPMC12641085
DOI10.1002/cpt.3750
发表日期2025-06-25
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:身体组成变化图;Figure 3:身体组成变化图;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。
摘要

摘要

About half of the world's population is living with overweight or obesity. Tirzepatide is an approved treatment for chronic weight management. We sought to characterize the exposure-response relationship for weight reduction in patients with overweight or obesity and quantify the associated changes in body composition. Monthly body weight measurements were available from 2,539 study participants in a phase 3 clinical trial investigating placebo, 5, 10, or 15 mg of tirzepatide administered once-weekly. The dependent variables used for modeling were fat-free mass (FFM) and fat mass. These FFM and fat mass values were calculated for each patient based on their total body weight, height, and sex. The exposure-response model revealed that administration of tirzepatide resulted in three times greater reduction of fat mass than that of FFM. This differential effect resulted in improved body composition over time. The model results showed good agreement with available data from a subset (10%) of clinical trial participants who had dual energy x-ray absorptiometry (DXA) measurements. For the same drug exposure, females achieved greater weight reduction than males. Study participants with higher baseline weight or body mass index at baseline had a slower rate of weight reduction and were expected to take longer to reach their nadir weight. We present and propose the use of a pharmacometric-based body composition model to describe weight reduction in future clinical trials investigating similar drugs in similar patient populations, in lieu of DXA scans. In such future trials, our approach can be used to describe exposure-response relationships, optimize doses, and investigate covariates, while considering potential differences in fat mass and FFM.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Visual predictive check for model of weight reduction—total body weight. The upper dotted line represents the 95th percentile of the observed data. The middle continuous line represents the 50th percentile of the observed data. The lower dotted line represents the 5th percentile of the observed data. The shaded areas represent the model‐predicted 95% confidence interval of the corresponding percentiles. Due to their high density, the observed data points have been removed from the plot to increase the clarity of the percentiles. The top four panels are for the training dataset. The bottom four panels are for the external evaluation dataset.
非 KM Figure
Figure 2Figure 2 Tirzepatide weight reduction model predictions for change from baseline fat mass (top row), FFM (middle row), and total weight (fat mass + FFM) [bottom row] correspond with DXA measurements from placebo and tirzepatide treatment arms. DXA , dual energy X‐ray absorptiometry; FFM , fat‐free mass; QW , once‐weekly. Virtual participants with obesity or overweight were simulated using the tirzepatide population weight reduction final model for the placebo or each tirzepatide treatment arm. Solid black lines denote the simulation median and the shaded area represents the 90th prediction interval. Symbols denote the change from baseline in individual DXA measurements.
非 KM Figure
Figure 3Figure 3 ( a ) A typical decrease in body weight as a sum of fat mass and fat‐free mass over time following tirzepatide doses of 5, 10, or 15 mg. ( b ) Typical change in body composition over time following tirzepatide doses of 5, 10, or 15 mg.
非 KM Figure
Figure 4Figure 4 Model‐predicted differences between males and females in response to various doses of tirzepatide. The continuous line is the mean prediction. The shaded area is the 95% confidence interval.
非 KM Figure
Figure 5Figure 5 Simulated weight reduction profiles for 15 mg tirzepatide dose in different patient populations.
非 KM Figure